David A Bond1, Jennifer A Woyach2. 1. Department of Internal Medicine, Division of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, 445D Wiseman Hall CCC, 410 W 12th Ave, Columbus, OH, 43210, USA. 2. Department of Internal Medicine, Division of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, 445D Wiseman Hall CCC, 410 W 12th Ave, Columbus, OH, 43210, USA. Jennifer.woyach@osumc.edu.
Abstract
PURPOSE OF REVIEW: While the Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL), current limitations include off-target toxicities and the development of resistance. In this review, we summarize the emerging data for alternative BTKi. RECENT FINDINGS: Second-generation BTKi include acalabrutinib, zanubrutinib, and tirabrutinib which offer greater BTK selectivity. While these agents may limit off-target toxicity, they do not overcome common mechanisms of ibrutinib resistance. Reversible BTKi including vecabrutinib and LOXO-305 inhibit BTK in the presence of C481S mutation, and non-selective reversible BTKi, including ARQ-531, may retain activity despite mutations within PLCG2. Early-phase studies are underway to establish the clinical efficacy and toxicity of these agents. A randomized trial of ibrutinib versus acalabrutinib is ongoing, and acalabrutinib may be an option for ibrutinib-intolerant patients. Results from ongoing trials of alternate BTKi will help to define their role in CLL therapy as single agents or in combination therapy.
PURPOSE OF REVIEW: While the Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL), current limitations include off-target toxicities and the development of resistance. In this review, we summarize the emerging data for alternative BTKi. RECENT FINDINGS: Second-generation BTKi include acalabrutinib, zanubrutinib, and tirabrutinib which offer greater BTK selectivity. While these agents may limit off-target toxicity, they do not overcome common mechanisms of ibrutinib resistance. Reversible BTKi including vecabrutinib and LOXO-305 inhibit BTK in the presence of C481S mutation, and non-selective reversible BTKi, including ARQ-531, may retain activity despite mutations within PLCG2. Early-phase studies are underway to establish the clinical efficacy and toxicity of these agents. A randomized trial of ibrutinib versus acalabrutinib is ongoing, and acalabrutinib may be an option for ibrutinib-intolerant patients. Results from ongoing trials of alternate BTKi will help to define their role in CLL therapy as single agents or in combination therapy.
Entities:
Keywords:
Acalabrutinib; B cell receptor; Tirabrutinib; Zanubrutinib
Authors: Tait D Shanafelt; Kari G Rabe; Neil E Kay; Clive S Zent; Diane F Jelinek; Megan S Reinalda; Susan M Schwager; Debbie A Bowen; Susan L Slager; Curtis A Hanson; Timothy G Call Journal: Cancer Date: 2010-10-15 Impact factor: 6.860
Authors: Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps Journal: Blood Date: 2008-01-23 Impact factor: 22.113
Authors: Apostolia-Maria Tsimberidou; Sijin Wen; Peter McLaughlin; Susan O'Brien; William G Wierda; Susan Lerner; Sara Strom; Emil J Freireich; L Jeffrey Medeiros; Hagop M Kantarjian; Michael J Keating Journal: J Clin Oncol Date: 2008-12-29 Impact factor: 44.544
Authors: Jennifer R Brown; John C Byrd; Paolo Ghia; Jeff P Sharman; Peter Hillmen; Deborah M Stephens; Clare Sun; Wojciech Jurczak; John M Pagel; Alessandra Ferrajoli; Priti Patel; Lin Tao; Nataliya Kuptsova-Clarkson; Javid Moslehi; Richard R Furman Journal: Haematologica Date: 2022-06-01 Impact factor: 11.047
Authors: Martin Wist; Laura Meier; Orit Gutman; Jennifer Haas; Sascha Endres; Yuan Zhou; Reinhild Rösler; Sebastian Wiese; Stephan Stilgenbauer; Elias Hobeika; Yoav I Henis; Peter Gierschik; Claudia Walliser Journal: J Biol Chem Date: 2020-03-17 Impact factor: 5.157
Authors: John C Byrd; Peter Hillmen; Paolo Ghia; Arnon P Kater; Asher Chanan-Khan; Richard R Furman; Susan O'Brien; Mustafa Nuri Yenerel; Arpad Illés; Neil Kay; Jose A Garcia-Marco; Anthony Mato; Javier Pinilla-Ibarz; John F Seymour; Stephane Lepretre; Stephan Stilgenbauer; Tadeusz Robak; Wayne Rothbaum; Raquel Izumi; Ahmed Hamdy; Priti Patel; Kara Higgins; Sophia Sohoni; Wojciech Jurczak Journal: J Clin Oncol Date: 2021-07-26 Impact factor: 44.544
Authors: Paolo Sportoletti; Filomena De Falco; Beatrice Del Papa; Stefano Baldoni; Valerio Guarente; Andrea Marra; Erica Dorillo; Chiara Rompietti; Francesco Maria Adamo; Loredana Ruggeri; Mauro Di Ianni; Emanuela Rosati Journal: Int J Mol Sci Date: 2021-06-22 Impact factor: 5.923
Authors: Maissa Mhibik; Erika M Gaglione; David Eik; Ellen K Kendall; Amy Blackburn; Keyvan Keyvanfar; Maria Joao Baptista; Inhye E Ahn; Clare Sun; Junpeng Qi; Christoph Rader; Adrian Wiestner Journal: Blood Date: 2021-11-11 Impact factor: 22.113